Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human allogeneic mesenchymal bone marrow cells (Medstar)
- Development stage
- Unknown
- Lead developer
- Medstar Health Research Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Human allogeneic mesenchymal bone marrow cells (aMBMC) is an investigational cell therapy developed by Medstar Health Research Institute for the treatment of advanced heart failure. The therapy consists of mesenchymal stem cells (MSCs) harvested from the bone marrow of healthy donors. When administered intravenously, these cells are thought to exert therapeutic effects through paracrine mechanisms, including the secretion of anti-inflammatory cytokines, pro-angiogenic factors, and anti-fibrotic molecules. This approach aims to promote myocardial repair, reduce systemic inflammation, and potentially improve heart function, particularly in patients with cardiomyopathy who have undergone left ventricular assist device (LVAD) implantation. The Phase IIa study (NCT02360930) specifically evaluated the safety and efficacy of serial intravenous doses in this high-risk population.
- Other names
- Allogeneic Mesenchymal Stem CellsAllogeneic Mesenchymal Bone Marrow CellsHuman Allogeneic Mesenchymal Bone Marrow Cells
Beyond the preview
Go deeper on human allogeneic mesenchymal bone marrow cells (Medstar).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human allogeneic mesenchymal bone marrow cells (Medstar).